Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Background: No standard chemotherapy is used as neoadjuvant therapy in triple negative breast cancer (TNBC). This study has compared carboplatin plus paclitaxel with commonly used epirubicin plus paclitaxel as neoadjuvant chemotherapy (NAC) in TNBC. Results: 91 patients with a median age of 47 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pin, Yin, Yi, Mo, Hongnan, Zhang, Bailin, Wang, Xiang, Li, Qing, Yuan, Peng, Wang, Jiayu, Zheng, Shan, Cai, Ruigang, Ma, Fei, Fan, Yin, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312408/
https://www.ncbi.nlm.nih.gov/pubmed/27447966
http://dx.doi.org/10.18632/oncotarget.10607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312408/
https://www.ncbi.nlm.nih.gov/pubmed/27447966
http://dx.doi.org/10.18632/oncotarget.10607

Ejemplares similares